Vista Robotics Quarterly Update

Q3 2023

Vista Robotics is creating the world's first active surgical robotic solution, specifically designed for spinal fusion surgeries. Our groundbreaking technology offers unprecedented robotic assistance for the intricacies and complexities involved in spinal fusion procedures, while also laying the groundwork for a robust robotic platform that can facilitate active surgical assistance in a myriad of future medical procedures.

As we continue to make rapid progress toward our product, market, and financing goals, we are pleased to offer this quarterly update to you. Please reach out to the Vista Robotics Executive Team for any questions or comments about the path and achievements that Vista is making.

R&D Progress

Peter Himes stands in front of the SpineNova system in our San Jose R&D Labs

The SpineNova system is over 90% complete, with the focus right now on software development for key parts of the system, in particular the surgical planning and discectomy trajectory control. Over the past quarter we have made tremendous strides in defining and executing on the entire software architecture. In specific, we have architected and coded the 3D reconstruction and segmentation software, the overall patient file and UI architecture, and machine – patient registration in 3D space. Controls for the discectomy and endplate preparation end effector are in place and surgical path algorithms are in development. Below shows the overall software and system architecture:

Vista Robotics, Inc
vistarobotic.com
1701 Fortune Drive, Suite E
San Jose, CA 95131



The overall system UI and integration work is also progressing, and the surgical planning piece is being developed as an element of this work. All key software elements are expected to be functionally ready for testing this quarter, with in house testing commencing in September. A video overview of SpineNova explaining all of its major features and benefits can be seen at this location https://drive.google.com/file/d/1gyB95v1hoCSTXLdDdUz11C3YeAH4dLis/view?usp=sharing and a more detailed view of the user interface and 3D reconstruction can be seen here https://drive.google.com/file/d/1v3FT2vK8qMT4Dc4KXInTT0eF3xbHLzTb/view?usp=sharing

Actual discectomy testing on cow discs are to begin in August, with ongoing testing for algorithm optimization. Testing on human cadavers is to take place from September through December, at Tier 1 labs led by UCSF and under the supervision of their leading spine and neurosurgeons. This is a necessary stage to verify and improve on our robot control algorithms, and to test and measure the efficacy of the Vista Robotics discectomy and endplate preparation end effector. Our goal is to have this R&D work progress to the point where we attain endorsement by the surgeons and Tier 1 institutions as to the efficacy and safety of the Vista solution, sometime in Q1 of next year.

Financing and Partnerships Progress

Vista Robotics completed its Seed Round of funding in December of 2022 with $500k of investment by key individuals and institutions. We are in discussions with additional investors who want to join with Vista in our journey with an extension of the Seed Round of $300k. As we get into the Tier 1 Labs for system testing and optimization, we will begin the promotion of our pre-A round, which is planned to carry us through FDA submittal, clearance, and market entry. Contact the Executive Team for more information on this exciting next stage.

An important part of our financing discussions at this point have been the deep and ongoing discussions with several institutions and funds in China, which will allow us to establish and open our Vista China office. This office will not only engage with the Chinese government regulatory bodies for education and approval, but also engage across China's spine and neurosurgery network to raise awareness for the Vista Robotics SpineNova solution and help to prepare the market for entry.

Market Engagement Progress

The US market remains our prime market and principal focus for R&D, FDA clearance, and eventual market entry. Our Board of Advisors and Clinical Staff represent Tier 1 institutions from across the US, including UCSF, Dignity Health, and UVA. This quarter we have expanded our clinical staff to include Dr. Kingsley Abode from the Mayo Clinic and Dr. Alphonse Lubansu from Erasme Hospital at the Université Libre de Bruxelles. These early advocates for the SpineNova system will also be our initial customers, and they will be training centers for future Vista Robotics users as well as important spokespersons for the company.



Nationally Recognized Spine Surgery and Neurosurgery Experts, and Experienced Medtronic Mazor Trainers

The China market is, by numbers, a larger addressable market than the US, though smaller by revenue numbers due to differences in payment structures and reimbursement rates. However, the large demand compels us to explore it as our secondary served market, and it is to this end that we have the ongoing engagement discussions with key provincial, government and private entities within China. Attaining clearance in the China market, unlike the US market, will require pre-trial clinical data to be

submitted, so the timing for clearance for the China market is expected to be 1 year later than the US market.

Other global markets of interest include certain European, Middle East and East Asian countries. While we have ongoing discussions of deep interest in the SpineNova solution, and we expect to see attractive market pull in many of these regions, our initial focus at this time is on the US market first, and China second. [Note that Dr Alphonse Lubansu, of the Erasme Hospital in Brussels, is an ardent supporter of Vista. He will be an important advocate for Vista as we decide how to enter the Greater European market.]

Organizational and Administrative Progress

Vista Robotics has established its HQ and R&D Center at 1701 Fortune Drive, San Jose California, in the heart of Silicon Valley.

Our total direct headcount is 9 persons, with additional software development team engaged by contract. Our administrative focus has been on preparing website and marketing collateral, and refining our pitch and financial planning.

Management Team

Roy (Sing-Fat) Chin
Co-Founder, Chairman
33 years as inventor for medical devices, three exits; Stryker, CTS (acquired by Boston Scientific), AFx （acquired by Guidant), AdcuraSpine

Christie Wang J.D.
Co-Founder, CEO
10 years of medical device commercialization/operation, regulatory and clinical, team management, Hewlett Packard/Agilent, AdcuraSpine

Peter Himes
VP of Business Development
33 years of international business development and strategic alliances 6 startups, National Semiconductor, Winbond, Haier

Brian Hauck
Product Dev - Hardware
20 years medtech R&D, Mechanical and Aeronautical Engineering, UC Davis. Arterica, Trivasular, Agilent

Nima Masoumi (Canada)
Software Lead
10 years in C-arm image-assisted surgical navigation system, 2D-3D image registration

Dehua Tan (Canada)
Software Architect
Provilla, acquired by TrendMicro
Computer vision and control

VISTA ROBOTICS

200 Years' of Medical Device and High Technology Startup Experience

Robin Bek
Product Dev – Electronics
20+ years in Medical Device R&D, over 30 patents, five exits. Covidien, J&J

Kai Ying (China)
COO
20+ years operation and management in semiconductor and medtech. Cypress, Vanguard, Cisco

James Bao
Advanced Software Development
35 years commercialization in spine US and Intl markets. Asculap, Tedan

Dawn Lissy (Consultant)
US Regulatory, quality system
Regulatory, testing, clinical for spine implants, instruments, surgical robotic system for 15 years, Founder of Empirical

India Software Development Team

Javed Badshah
Project Lead

Aftab Pangarkar
Co-ordinator UI / UX

Parag Mane
Quality Testing Engineer

Komal Konde
Software Engineer

Dhrutika Patil
Software Engineer

VISTA ROBOTICS

Vista Robotics, Inc
vistarobotic.com
1701 Fortune Drive, Suite E
San Jose, CA 95131

Focus for the Upcoming Quarters

As described above, the focus for the upcoming quarters is really in 2 camps: first, an unwavering focus on R&D and SpineNova system testing and optimization, both on the software modules (including surgical planning, active registration, UI and system integration) and on the hardware performance (through cow disc and human cadaver testing and optimization.) And second, the financing of the company including the offered extension of the Seed Round which is now open and initializing the engagement and promotion of Vista Robotics to potential pre-A investors.

This is an exciting time for the entire Vista Robotics team, and we are so proud to offer these updates to you. Thanks for your interest and we look forward to discussing our progress in more detail.

With warm regards,

Christie (Lan) Wang
CEO
Vista Robotics, Inc.

Vista Robotics, Inc
vistarobotic.com
1701 Fortune Drive, Suite E
San Jose, CA 95131